SingHealth

Helping clients navigate today's challenging healthcare environment with innovative, next generation solutions for Healthcare IT.

[WebMD @WebMD]

Having a cup of coffee with milk may do more than put you in a good mood every morning. The combination may actually inhibit inflammation, say researchers at the University of Copenhagen. https://t.co/gYWh3hVuDq

[SingHealth @SingularHealth]

Great talk this morning, Joshua. Thanks for participating from Oklahoma.

[Joshua Muia @joshuamuia]

Thank you the Division of Hematology @DukeHealth @dukemedicine, & Gow Arepally for hosting me this morning for the Hematology Case Conference. I enjoyed interacting with everyone and sharing my work on #ADAMTS13, #VWF, & #TTP.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES DrKantiRai @NorthwellHealth suggests that it is too soon to use Venetoclax as first line Rx for CLL, reminding us of the cautionary tale of late emerging immune mediated toxicities with idelalisib. There may be as yet unknown toxicities that mandate caution.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrDanielleBrander @DukeCancer presents argument that Venetoclax leads to more MRD negativity in CLL (predictive for better outcomes) and is well tolerated. Nonetheless, need close monitoring for cytopenias and other toxicity.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrMattMcKinney@Duke summarizes debate over #brentuximab: Value of A + AVD vs ABVD in HodgkinDz is unclear; still need long term outcome data. A+AVD may only be right in subgroups; needs careful discussion with pt.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrMattMcKinney@Duke argues A+AVD has more toxicity than ABVD in Stg III/IV HodgkinDz. Alternate strategy could be dropping Bleo: ClinTrial showed no diff in OS for pts randomized to ABVD x 4 vs AVD x 4 after CR on PET following ABVD x 2 cycles

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
Dr AhmedGalal @Duke debates benefits of #brentuximab in Stg III/IV HodgkinDz. Pulm toxicity w ABVD unpredictable and sometimes fatal. Notes increased periph neuropathy/febrile neutropenia; fewer deaths during & after treatment w A+AVD but OS data not yet mature

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrMichelKhouri@Duke notes 3D echo LVEF more accurate/reproducible than usual 2D Echo. Emerging modality of Speckle-tracking strain echo reveals tissue deformation – ie damage earlier that echo LVEF. Combo of strain/troponin improve predictability of CVD

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrMichelKhouri@Duke urges prevention, early detection/treatment of cardiac toxicity/disease in pts with cancer. Accelerated CV aging seen in pts with cancer and cancerRx may be due to proinflam mediators in both CVD/Ca.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrAraMetjian @Duke debates the need for longterm AC in first unprovoked DVT/PE; notes more often than not, pts don’t recur. Longterm AC increases risk of bleeding/death in some who would never recur.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrEwaWysokinska @Duke urges longterm continued AC in pts with first unprovoked DVT/PE given high risk of recurrence. Notes the novel AC agents have equal efficacy but decreased bleeding risk c/w warfarin. Reassess risk/benefit annually.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
DrCarlosDecastro @DUKE argues NextGenSequ’g doesn’t impact diagnosis. Impact on prognosis does not yet translate into better/different response to treatment. Emerging data for TP53. MDS is complex and may require computational modeling.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES
Dr. Pemmarajuf MD Anderson @doctorpemm argues NextGenSequ’g should be done in all MDS pts despite costs, etc. Adverse markers (#ASXL1 #RUNX1 #TP53 #>/=3 mutations) and favorable markers (#SB3F1) can impact treatment options

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES Dr William Blum of @emoryhealthcare indicates Gemtuzumab Ozogamicin #Mylotarg has signif impact on EFS and RFS for CD33+ AML with favorable Intermediate cytogentics even if OS not significantly impacted fractionated dosing as in #ALFA-0701 FrenchTrial reduces tox

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES Dr Naveen Pemmaraju of MDAnderson reports purple #Vyxeos statistically improves OS in AML pts 60-75 even up to PS 2. Cautioned prolonged cytopenias but notes more pts went on to Stem cell transplant (34%) compared with 7+3 standard Rx (25%) even in pts over 70.

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES Dr. Lindsay Rein asks “Should we rock the boat with improved survival from TKIs in CML?" Notes negative health impact in younger pts; #financialtox overall; cautions not yet enough data to stop TKIs as SOC #ImatinibWithdrlSyndrom (?other TKIs) needs more research

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES DrJoeMoore–TKIs have changed the lives of pts with CML. Moore cautions that TKIs can be stopped after prolonged treatment (>3 yrs) with durable MMR, only select pts willing/able to follow strict observation guidelines; restart TKI promptly 4 relapse occurs

[Duke Cancer Network @DukeCancerNETWK]

#DUKEhemeDEBATES Drs Rizzieri/Chao @Duke explore possibility of overcoming immune evasion by AML through #microtransplantation. Clinical trial for pts aged >65 to open @Duke soon.

[SingHealth @SingularHealth]

I wonder if it can translate between left wing and right wing discourse? https://t.co/PBFaIZ2MjB

[Singularity @singularityu]

Google has built earbuds that translate 40 languages in real time https://t.co/7QtQjg0wVM

[Digital Health News @digihealthnews]

How doctors can monitor health based on tea-making abilities https://t.co/lGa7iThgjh @Philips #digitalhealth